Free Trial
NASDAQ:NRSN

NeuroSense Therapeutics (NRSN) Stock Price, News & Analysis

NeuroSense Therapeutics logo
$1.10 +0.02 (+1.85%)
Closing price 03:59 PM Eastern
Extended Trading
$1.06 -0.04 (-3.64%)
As of 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About NeuroSense Therapeutics Stock (NASDAQ:NRSN)

Key Stats

Today's Range
$1.08
$1.11
50-Day Range
$1.04
$1.19
52-Week Range
$0.51
$2.25
Volume
90,563 shs
Average Volume
244,770 shs
Market Capitalization
$15.03 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Hold

Company Overview

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.

Remove Ads

NeuroSense Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
12th Percentile Overall Score

NRSN MarketRank™: 

NeuroSense Therapeutics scored higher than 12% of companies evaluated by MarketBeat, and ranked 896th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of NeuroSense Therapeutics is -1.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of NeuroSense Therapeutics is -1.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about NeuroSense Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    1.47% of the float of NeuroSense Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    NeuroSense Therapeutics has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in NeuroSense Therapeutics has recently increased by 2.09%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    NeuroSense Therapeutics does not currently pay a dividend.

  • Dividend Growth

    NeuroSense Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.47% of the float of NeuroSense Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    NeuroSense Therapeutics has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in NeuroSense Therapeutics has recently increased by 2.09%, indicating that investor sentiment is decreasing.
  • News Sentiment

    NeuroSense Therapeutics has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for NeuroSense Therapeutics this week, compared to 1 article on an average week.
  • Search Interest

    2 people have searched for NRSN on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, NeuroSense Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    27.40% of the stock of NeuroSense Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 1.04% of the stock of NeuroSense Therapeutics is held by institutions.

  • Read more about NeuroSense Therapeutics' insider trading history.
Receive NRSN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NeuroSense Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

NRSN Stock News Headlines

NeuroSense Therapeutics (NRSN) to Release Quarterly Earnings on Monday
Has Trump finally met his match?
Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance to walk away with gains as high as 235%, 459%, and 700% - all while the stock market got cut in half. Could he be right again?
NeuroSense regains Nasdaq compliance
See More Headlines

NRSN Stock Analysis - Frequently Asked Questions

NeuroSense Therapeutics' stock was trading at $1.20 on January 1st, 2025. Since then, NRSN shares have decreased by 8.3% and is now trading at $1.10.
View the best growth stocks for 2025 here
.

NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) posted its quarterly earnings results on Wednesday, December, 18th. The company reported ($0.11) earnings per share (EPS) for the quarter.

NeuroSense Therapeutics (NRSN) raised $13 million in an initial public offering (IPO) on Thursday, December 9th 2021. The company issued 2,000,000 shares at a price of $6.00-$7.00 per share.

NeuroSense Therapeutics' top institutional investors include Citadel Advisors LLC (1.86%) and Jane Street Group LLC (0.47%).

Shares of NRSN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that NeuroSense Therapeutics investors own include Predictive Oncology (POAI), Ford Motor (F), Bank of America (BAC), JPMorgan Chase & Co. (JPM), Wells Fargo & Company (WFC), Abbott Laboratories (ABT) and Energy Select Sector SPDR Fund (XLE).

Company Calendar

Last Earnings
12/18/2024
Today
3/25/2025
Next Earnings (Estimated)
4/04/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:NRSN
Fax
N/A
Employees
10
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-11,280,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
($0.14) per share
Price / Book
-7.75

Miscellaneous

Free Float
9,922,000
Market Cap
$14.83 million
Optionable
Not Optionable
Beta
1.28
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

This page (NASDAQ:NRSN) was last updated on 3/25/2025 by MarketBeat.com Staff
From Our Partners